Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MIRCETTE vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and desogestrel; estrogen and progestin inhibit gonadotropin release, suppressing ovulation and altering cervical mucus and endometrial receptivity.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women aged ≥15 years who have reached menarche and desire contraception
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet daily for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.015 mg ethinyl estradiol and 2 mg chlormadinone acetate. Route: oral.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Desogestrel active metabolite etonogestrel: 21-24 hours; ethinyl estradiol: 12-14 hours
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol: primarily metabolized via CYP3A4; undergoes first-pass hepatic metabolism, conjugated to sulfate and glucuronide. Desogestrel: prodrug converted to active metabolite etonogestrel via CYP2C9 and CYP3A4; further metabolized by reduction and glucuronidation.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Urine (50-60% as metabolites, <10% unchanged), feces (30-40% as metabolites)
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Desogestrel: >95% (albumin, SHBG); ethinyl estradiol: >97% (albumin)
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Desogestrel: 1.5 L/kg; ethinyl estradiol: 2.9 L/kg
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Desogestrel (as etonogestrel): 76% (oral); ethinyl estradiol: 55% (oral, variable due to first-pass metabolism)
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No specific dose adjustment recommended. Use with caution in severe renal impairment due to potential fluid retention.
No data available for fictional drug ALYACEN 777.
Contraindicated in severe hepatic disease (Child-Pugh class C) or liver tumors. For mild to moderate impairment (Child-Pugh A-B), use with caution; contraindicated if liver function tests are persistently abnormal.
No data available for fictional drug ALYACEN 777.
Not indicated in prepubertal females. Safety and efficacy in postmenarchal adolescents established based on adult studies.
No data available for fictional drug ALYACEN 777.
Contraindicated in postmenopausal women. Not indicated for use in elderly due to lack of efficacy for contraception.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events from COC use, especially in women >35 years old who smoke ≥15 cigarettes/day. Do not prescribe to women who smoke and are over 35.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Increased risk of thrombotic disorders (VTE, MI, stroke), especially in smokers and women with hypertension or other risk factors.,Liver disease: discontinue if jaundice or impaired liver function develops.,Elevated blood pressure: monitor and discontinue if hypertension develops.,Gallbladder disease: possible increased risk.,Carbohydrate and lipid metabolism: monitor in diabetic or hyperlipidemic patients.,Headache: may exacerbate migraine or cause new-onset headache.,Uterine bleeding: irregular bleeding may occur.,Depression: discontinue if significant depression occurs.,Ocular effects: discontinue if sudden partial/complete vision loss occurs.,Carcinoma: possible increased risk of breast/cervical cancer, but evidence uncertain.
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Carcinoma of endometrium or other known/suspected estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component,Smoking and age >35 years,Migraine with aura (current or history) in women over 35
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No significant food interactions known; however, grapefruit juice may increase estrogen levels via CYP3A4 inhibition, though clinical significance is low. Avoid St. John's wort as it induces metabolism of ethinyl estradiol and desogestrel, potentially reducing contraceptive efficacy.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester exposure associated with congenital anomalies (cardiovascular, limb reduction, neural tube defects). Second/third trimester exposure may cause fetal adrenal suppression, virilization of female fetus, and metabolic disturbances.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Excreted into breast milk. M/P ratio unknown. Potential for serious adverse effects in nursing infant (adrenal suppression, hormonal imbalance). Contraindicated during breastfeeding per manufacturer.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
No dose adjustments applicable as drug is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) would theoretically require dose increase, but use is not recommended.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
Mircette is a monophasic oral contraceptive containing 0.15 mg desogestrel and 0.02 mg ethinyl estradiol. It has a shorter hormone-free interval (2 days of placebo) than traditional 7-day placebo regimens, which may reduce breakthrough ovulation and improve suppression of ovarian activity. Counsel patients that the first 7 days of the initial cycle may require a backup method. Desogestrel has low androgenicity and may improve acne. Use with caution in patients with migraine with aura or increased cardiovascular risk.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one tablet at the same time daily; missed pills increase pregnancy risk.,If you miss a pill, refer to the package insert for instructions; use backup contraception if needed.,Mircette may reduce menstrual bleeding and cramping; do not skip pills during withdrawal bleeding.,Smoking while on this pill increases risk of blood clots, especially in women over 35.,Some antibiotics and anticonvulsants may reduce effectiveness; inform your healthcare provider of all medications.,Do not take if you have a history of blood clots, certain cancers, or liver disease.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MIRCETTE vs ALYACEN 777, answered by our medical review team.
MIRCETTE is a Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel; estrogen and progestin inhibit gonadotropin release, suppressing ovulation and altering cervical mucus and endometrial receptivity.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MIRCETTE and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MIRCETTE is: One tablet daily for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.015 mg ethinyl estradiol and 2 mg chlormadinone acetate. Route: oral.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MIRCETTE and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MIRCETTE is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester exposure associated with congenital anomalies (cardiovascular, limb reduction, neural tube defects). Second/. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.